Enhancing a new treatment for pancreatic cancer using advanced technology
Improving the potency of novel PRMT5 inhibitor with nanocrystal technology to treat pancreatic cancer
This study is looking at a new treatment for pancreatic cancer that uses tiny crystals to make a special medicine work better when combined with other common treatments, aiming to help patients live longer with fewer side effects.
Quick facts
| Grant type | R03 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Indiana University Indianapolis NIH-funded |
| Lab location | 1 site (Indianapolis, United States) |
| Project ID | NIH-11041283 on NIH RePORTER |
What this research studies
This research focuses on improving a novel inhibitor of PRMT5, a protein linked to pancreatic cancer, by utilizing nanocrystal technology. The goal is to enhance the effectiveness of this treatment when combined with existing therapies like Gemcitabine and nano albumin-bound Paclitaxel. By targeting the mechanisms that contribute to cancer resistance, the research aims to provide a more potent and less toxic treatment option for patients suffering from pancreatic ductal adenocarcinoma. Patients may benefit from a new therapeutic approach that could potentially improve survival rates and reduce side effects.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with pancreatic ductal adenocarcinoma who have not responded well to current treatments.
Not a fit: Patients with other types of cancer or those who have already exhausted all treatment options may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and less toxic treatment options for pancreatic cancer patients.
How similar studies have performed: Previous research has shown promise in targeting PRMT5 in cancer therapy, indicating that this approach could be a significant advancement in treatment.
Where this research is happening
Indianapolis, United States
- Indiana University Indianapolis — Indianapolis, United States (Active)
Researchers
- Principal investigator: Lu, Tao — Indiana University Indianapolis
- Study coordinator: Lu, Tao
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.